Bone Marrow Neoplasm, Lymphoma
Conditions
Brief summary
Newly diagnosed lymphoma patients were recruited for FDG PET/CT and PET/CT guided bone marrow biopsy. All the patients also underwent routine bone marrow sampling from the posterior superior iliac spine.
Detailed description
Newly diagnosed patients underwent FDG PET/CT for whole-body staging. All the PET/CT images were analyzed by a qualified nuclear medicine physician. The bone marrow FDG uptake was classified as negative, focal, multifocal and diffuse marrow uptake. A PET/CT guided metabolic bone marrow sampling from the FDG avid marrow-based lesion was done. However, patients with diffuse FDG avidity or no uptake in the marrow differed for PET-guided biopsy. All the patients underwent routine trephine bone marrow sampling. Bone marrow infiltration (final diagnosis) was established based on trephine bone marrow sampling and FDG PET/CT targeted bone marrow biopsy results in the present study. The results of both the biopsies were correlated with the final diagnosis.
Interventions
PROCEDUREPET Guided Bone Marrow Biopsy
The results of PET/CT images were discussed with the referring physician. PET/CT targeted metabolic marrow biopsy was planned two hours after the whole body diagnostic imaging or on a subsequent day one hour after injecting 2-3 mCi of FDG to minimize the radiation exposure burden to the interventionist. Society of Interventional Consensus guidelines was followed for image-guided biopsy. The bone marrow biopsy was done under the PET/CT guidance using the same PET/CT scanner with the help of an automated robotic arm (ARA) workstation
PROCEDURETrephine Bone Marrow Biopsy
All the participants underwent trephine bone marrow biopsies from the bilateral posterior superior iliac spine before treatment planning.
Sponsors
Post Graduate Institute of Medical Education and Research, Chandigarh
Study design
Observational model
OTHER
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Inclusion criteria
1. Newly diagnosed cases of lymphoma (both HL and NHL). 2. Hypermetabolic bone marrow lesions on staging 18F-FDG PET/CT, which are accessible for biopsy. 3. Aged between 18 -80 years. 4. Informed consent prior to the procedure.
Exclusion criteria
1. Previously treated/relapsed lymphoma. 2. Initiation of therapy (chemotherapy, radiation therapy) and/or hematopoietic growth factor injections before 18F-FDG PET/CT or BMTB. 3. Patients who underwent a prior BMTB to evaluate the role of BMI. 4. Patients with pre-existing bleeding diatheses like hemophilia, coagulopathy, INR \> 1.2 and platelet counts \< 50,000/mm3, 5. Patients who refuse to provide informed consent. 6. No 18F FDG avid skeletal lesions. 7. Pregnant/Lactating female patients. 8. Non-cooperative patients.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Comparison results of PET guided bone marrow biopsy with trephine bone marrow biopsy | three months | The final diagnosis of bone marrow infiltration was based on the pathology findings of trephine bone marrow biopsy and FDG PET/CT targeted bone marrow biopsy. The diagnostic accuracy (in percentage) of FDG PET/CT guided metabolic bone marrow biopsy was compared with the accuracy (in percentage) of trephine bone marrow biopsy with respect to final diagnosis. |
Countries
India
Outcome results
None listed